PharmaReg AI helps biotech and biopharma teams define, pressure-test, and execute regulatory strategies that maximize approval probability, accelerate timelines, and anticipate FDA and global agency objections before they arise.
Why Strategy Comes First
A well-designed molecule with a flawed regulatory strategy will fail. Most development setbacks — unexpected agency requests, clinical holds, complete response letters — are predictable and preventable with the right upfront strategic planning informed by real regulatory precedent.
The FDA's own adoption of AI tools like Elsa, and the January 2026 joint FDA-EMA guiding principles for AI in drug development, mean that regulatory strategy must now be designed to meet an increasingly sophisticated, AI-augmented review process. PharmaReg AI helps you stay ahead of this curve.
Many programs pursue a standard review when expedited designations apply — Fast Track, Breakthrough Therapy, Accelerated Approval, or PRIME — leaving months of review time and competitive advantage on the table from the outset.
Selecting primary endpoints that regulators will not accept as pivotal evidence is one of the most expensive mistakes in drug development — often not discovered until Phase III is already complete, costing hundreds of millions of dollars.
Sponsors who invest in pre-IND meetings, Type B interactions, and proactive FDA alignment consistently outperform those who engage regulators only in response to deficiencies — by months of development time.
Strategy Services
From target product profile definition to BLA submission planning, we build evidence-grounded strategies that keep your program on the fastest credible path to approval.
Defining your desired and minimum acceptable product profile — indication, population, endpoints, safety profile, and labeling claims — anchored in current regulatory precedent and real agency expectations.
Identification and pursuit of Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, Orphan Drug Designation, and EMA PRIME programs — supported by AI-generated precedent analysis for each application.
Pre-IND, Type A, B, and C FDA meeting request preparation, briefing document authoring, and strategic Q&A development — ensuring your team enters each interaction with the right questions and aligned expectations.
Multi-jurisdictional strategy for simultaneous or sequential filings across FDA, EMA, MHRA, PMDA, TGA, and Health Canada — minimizing data duplication and reducing the total cost of global development.
Regulatory-grounded input on primary and secondary endpoint selection, patient population definition, trial design, and statistical considerations — aligned with current FDA and EMA guidance and analogous approval precedents.
Structured risk-benefit assessment frameworks tailored to your indication and patient population — including benefit-risk documents aligned with FDA PDUFA commitments, the EMA's benefit-risk methodology, and the 2026 joint FDA-EMA AI guiding principles.
Our Methodology
We conduct a comprehensive review of your existing data package, development history, competitive landscape, and proposed indication — mapping regulatory risks, pathway options, data gaps, and strategic opportunities before any pathway commitment is made.
Our platform analyzes analogous FDA and global agency decisions — approval packages, AdCom transcripts, complete response letters, and label negotiations across your therapeutic area — grounding your strategy in documented agency behavior rather than assumptions or general industry knowledge.
We develop two to three strategic scenarios — each with probability assessments, timeline projections, resource requirements, and key risk factors — enabling your leadership team to make an informed, board-ready pathway decision.
Regulatory strategy is a living document. We provide continuous advisory support — adapting your strategy as new clinical data emerges, agency feedback is received, competitive programs advance, and the regulatory landscape evolves.
Strategic Impact
Strategy Coverage
Our regulatory strategy practice spans the full range of development programs, approval pathways, designation types, and agency interaction formats across all major global jurisdictions.
PharmaReg AI monitors global regulatory activity in real time — agency guidance, AdCom decisions, label precedents, enforcement patterns, and competitive filings — and delivers synthesized, program-specific intelligence to your team before it becomes common knowledge.
Why Intelligence Changes Everything
The regulatory landscape in 2025–2026 is shifting faster than at any point in recent history — the FDA's deployment of internal generative AI tools, the joint FDA-EMA AI guiding principles, the EU AI Act, and a rapidly expanding body of product-specific precedents are all changing what regulators expect and how they evaluate submissions.
Most development teams learn about these changes too late, if at all. PharmaReg AI's intelligence platform ensures your regulatory scientists and development leadership always operate with the most current, curated, and program-relevant regulatory insight available.
FDA and global agencies issue hundreds of draft and final guidances each year. Missing a relevant update — or misinterpreting its strategic implications — can set a program back by an entire development cycle or more.
Understanding how regulators have positioned every approved product in your drug class — indication language, safety labeling, REMS requirements, post-market commitments — provides the clearest signal of what they will require from you.
AdCom discussions consistently surface agency thinking months or years before formal guidance is issued. Our AI synthesizes transcripts and voting rationale to extract strategic signals before they become industry knowledge.
Intelligence Services
From real-time monitoring alerts to deep competitive dossiers, we deliver intelligence at the speed and depth your development timelines require.
Continuous surveillance of FDA, EMA, PMDA, MHRA, Health Canada, and TGA publications, with AI-generated summaries and program-specific impact assessments delivered within 24 hours of release.
Deep-dive analysis of approved product labels, indication language, risk communication requirements, and REMS precedents across your therapeutic area — mapped directly to your own program's data and claims.
AI synthesis of AdCom meeting transcripts, briefing documents, and voting patterns — with expert-curated strategic takeaways mapped to your specific program, indication, and upcoming interactions with the FDA.
Bespoke intelligence reports mapping the complete regulatory environment for your molecule across all target markets — approval pathways, data requirements, precedent products, and jurisdiction-specific nuances.
Ongoing monitoring of FDA warning letters, complete response letters, drug safety communications, FAERS signals, and pharmacovigilance actions relevant to your drug class and patient population.
Monthly briefings tracking competitors' regulatory filings, approval timelines, label expansions, post-market commitments, and clinical trial activity — synthesized into strategic implications for your own program.
Our Approach
We define your therapeutic area, target mechanisms, competitive set, target markets, and specific intelligence priorities — building a customized monitoring profile that filters signal from noise for your program specifically.
Our AI platform continuously ingests guidance documents, Federal Register notices, EMA opinions, agency press releases, label databases, clinical trial registries, and scientific literature across 50+ curated authoritative sources.
Raw signals are processed by generative AI to extract relevance and draft structured summaries, then reviewed and contextualized by our regulatory scientists — who assess program impact, prioritize action items, and add strategic perspective.
Intelligence is delivered as weekly digests, on-demand deep dives, or integrated into your team's planning cycles — with clear action flags and regulatory risk ratings for each finding, aligned to your development milestones.
Intelligence Impact
Intelligence Scope
Our monitoring covers every major regulatory input that shapes drug and biologic development strategy — across agencies, document types, and therapeutic areas globally.
PharmaReg AI combines deep regulatory expertise with generative AI to produce submission-ready documents at a fraction of the traditional cost and timeline — with every deliverable reviewed and signed off by an experienced regulatory scientist. Now also optimized for FDA's AI-powered Elsa review system.
The Cost of Traditional Document Generation
Traditional regulatory writing is slow, expensive, and increasingly misaligned with how the FDA now evaluates submissions. With the FDA's own deployment of generative AI tools for review, documents that are not optimized for AI-assisted reading — with clear structure, consistent terminology, and complete cross-referencing — face a new class of review risk.
PharmaReg AI produces documents that are submission-ready for both human reviewers and AI-augmented FDA evaluation — faster, at a fraction of the cost, with every section reviewed by an expert regulatory scientist before delivery.
Senior regulatory consultants bill $300–$600 per hour. A single IND package can exceed $150,000 in writing fees alone. Generative AI, combined with expert oversight, eliminates the majority of manual drafting cost while maintaining scientific quality.
Regulatory writers spend the majority of their time on structural formatting, cross-referencing, and reformatting predictable, templated content. Our AI handles the full drafting and assembly layer in hours, not months.
With the FDA's Elsa system now evaluating submissions, documents with inconsistent terminology, poor cross-referencing, or dense narrative without logical structure face higher rates of information requests and review delays.
Documentation Services
From first-in-human INDs to complex BLAs, marketing authorization applications, and agency response documents — AI-drafted, expert-reviewed, and optimized for both human and AI-assisted FDA evaluation.
Complete Investigational New Drug packages including clinical protocols, investigator brochures, CMC sections, and pharmacology/toxicology summaries — eCTD-structured, expert-reviewed, and ready for FDA submission.
New Drug Application and Biologics License Application modules, nonclinical summaries, clinical overviews, integrated summaries of safety and efficacy — AI-drafted and formatted to current FDA submission standards.
Chemistry, Manufacturing and Controls narratives, drug substance and product specifications, stability protocols and reports, and manufacturing process descriptions — structured to ICH Q8, Q9, and Q10 standards.
Phase I–III clinical protocols, statistical analysis plans, clinical study reports, and REMS documents — AI-drafted to ICH E6 GCP standards and structured for AI-optimized FDA review by Elsa and human reviewers alike.
European MAA, Module 2 CTD summaries, and non-US submissions for EMA, MHRA, PMDA, Health Canada, and TGA — adapted to each jurisdiction's specific formatting requirements and regional scientific expectations.
Rapid-turnaround complete response letters, information request responses, and pre-NDA/BLA meeting briefing documents — structured to directly address AI-generated and human agency queries with traceable evidence references.
Our Process
Your dedicated regulatory scientist reviews your full data package, therapeutic area, and target indications. We define the optimal document set, eCTD module structure, and delivery timeline — and identify all data gaps before any writing begins.
Our generative AI workflows ingest your source data — preclinical reports, clinical datasets, manufacturing records, prior agency correspondence — and produce structured, eCTD-compliant first drafts within 24–72 hours, optimized for both human and AI-assisted FDA review.
Every section is reviewed by an experienced regulatory scientist for scientific accuracy, regulatory compliance, internal consistency, and alignment with the FDA's current guidance expectations. No document leaves our team without human expert sign-off.
You receive final documents in your preferred format with a regulatory review memo summarizing key authoring decisions. We remain engaged for agency response cycles, amendment drafting, and any information requests that follow submission.
Documentation Impact
Document Coverage
Our team and platform are fluent across every major submission type, ICH guideline, and global regulatory agency relevant to drug and biologic development worldwide.
PharmaReg AI transforms how regulatory teams operate — streamlining submission workflows, document management, compliance tracking, and post-approval reporting so your team spends less time on administration and more time advancing your pipeline.
The Operational Reality
Regulatory affairs teams at most biotech and biopharma companies spend a disproportionate share of their time on operational tasks — version control, submission tracking, document formatting, archive management, and compliance reporting — at the expense of the strategic and scientific work that actually advances programs.
PharmaReg AI re-engineers these workflows with AI-augmented processes that eliminate operational burden, reduce error rates, and provide real-time portfolio visibility — while maintaining the GxP compliance and audit trail integrity that regulated environments require.
Regulatory submissions span dozens of modules, multiple reviewers, and months of revision cycles. Without centralized, real-time tracking, programs miss deadlines and leadership lacks visibility until it is too late to course-correct.
Version control failures, inconsistent naming conventions, and unsynchronized document sets are endemic across the industry — generating audit findings, rework cycles, and submission delays that compound over time.
IND annual reports, PSUR/PBRER safety updates, post-market commitments, field alert reports, and labeling changes create an expanding operational backlog that grows with every approved or active product in your portfolio.
Operations Services
We redesign and augment your regulatory operating model with AI-driven workflows, purpose-built tooling, and expert oversight that scales as your portfolio grows.
End-to-end eCTD compilation, quality review, and publishing — including lifecycle management, sequence planning, and validation against FDA ICH M8 and emerging eCTD v4.0 technical specifications.
Implementation and ongoing management of AI-augmented document control systems with controlled versioning, complete audit trails, electronic signature workflows, and 21 CFR Part 11-compliant archiving by design.
Real-time portfolio dashboards tracking submission status, agency correspondence, PDUFA dates, information request timelines, and action item ownership — a single authoritative source of truth for all active programs.
Systematic tracking and preparation of post-market commitments, IND annual reports, PSUR/PBRER periodic safety reports, field alert reports, and labeling updates — with proactive deadline management across your full portfolio.
For early-stage companies building their regulatory function from the ground up, we provide operating model design, SOP library development, system architecture, and interim regulatory leadership — tailored to your stage and near-term portfolio needs.
Assessment, design, validation, and implementation of generative AI tools within your regulated regulatory function — including computer systems validation (CSV) documentation, SOP updates, change management, and training aligned with FDA and EU AI Act requirements.
Our Methodology
We conduct a structured review of your current regulatory operating model — processes, systems, team structure, and compliance posture — and benchmark against life sciences industry best practices to identify the highest-impact improvement opportunities.
Based on the assessment, we co-design the target operating model — embedding AI augmentation at optimal workflow points while maintaining GxP compliance, audit trail integrity, and regulatory validation requirements specific to your organization and portfolio.
Our team manages the full implementation of new tools, processes, and AI-powered workflows — including user training, SOP library updates, system validation documentation (CSV / GAMP 5), and hands-on transition support through go-live.
Post-implementation, we function as a seamless extension of your internal team — managing submissions, monitoring compliance deadlines, conducting periodic process reviews, and adapting your operating model as your portfolio and the regulatory environment evolve.
Operational Impact
Operations Coverage
Our operational support spans every major regulatory function activity — from pre-submission document architecture through post-market compliance, lifecycle management, and regulatory function transformation.
RegEZ is PharmaReg AI's purpose-built regulatory platform for biotech and biopharma teams. Ask any regulatory question, generate any document, research any precedent, and manage any submission — faster, cheaper, and smarter than anything that exists today.
Access the Platform
When RegEZ launches, you will be able to access the full platform directly from this page. The app link will be live at the address below. In the meantime, join our early access list to be first in line and receive a complimentary onboarding session with our regulatory team.
Your AI-powered regulatory co-pilot for strategy, intelligence, documentation, and operations — built exclusively for biotech and biopharma teams.
ⓘ This link will go live at RegEZ launch. Contact us to join the early access waitlist.
Platform Capabilities
RegEZ brings together PharmaReg AI's four service areas into one integrated, AI-powered workflow platform — built for speed, accuracy, and regulatory compliance.
Ask any regulatory question — FDA pathway options, ICH guideline requirements, precedent products, agency expectations, compliance requirements — and receive expert-level, sourced answers in seconds, available 24/7.
Generate first drafts of INDs, NDA/BLA modules, CMC sections, clinical study protocols, investigator brochures, and agency response documents — structured to current eCTD standards and optimized for FDA's AI-assisted Elsa review system.
Real-time monitoring of FDA, EMA, PMDA, and global agency publications — with AI-generated program-specific impact summaries, competitor label alerts, AdCom analysis, and enforcement tracking, all in one dashboard.
AI-guided regulatory pathway analysis, target product profile builder, expedited designation eligibility screening, and agency meeting preparation — grounded in thousands of real precedent decisions and current agency guidance.
Real-time portfolio dashboard tracking eCTD submission status, PDUFA dates, post-approval commitment deadlines, agency correspondence, and action item assignments — full portfolio visibility in one place.
Instantly search and analyze approved product labels, complete response letters, AdCom transcripts, and regulatory filing summaries across FDA, EMA, and PMDA — to ground every strategic and documentation decision in verified regulatory precedent.
How RegEZ Works
Type any regulatory question, request any document, search any precedent, or describe your program and ask for a pathway recommendation. RegEZ understands the full context of drug and biologic regulatory affairs — no need to know the right terminology before you start.
RegEZ's regulatory-trained AI generates answers, document drafts, intelligence summaries, or strategic analyses — drawing on current FDA and global agency guidance, approved product databases, ICH guidelines, and verified regulatory precedents.
For substantive deliverables — strategy memos, full document modules, regulatory analyses — a PharmaReg AI regulatory scientist reviews the output for accuracy, compliance, and program fit before you receive the final version.
Use answers directly, export documents in eCTD-ready formats, integrate intelligence into your planning sessions, or iterate on strategy scenarios in real time — with a full audit trail of all interactions for regulatory compliance documentation.
Early Access
From solo regulatory scientists to enterprise biopharma portfolios, RegEZ scales with your needs. Early access members receive preferred pricing and priority onboarding.
Get in Touch
Whether you are preparing a first IND, scaling a regulatory function, navigating a complex global submission, or joining the RegEZ early access list — our team will assess your needs and propose a tailored engagement with no obligation.